Evaxion Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Evaxion Biotech AS
EVAX Stock  USD 5.05  0.25  5.21%   
Evaxion Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Evaxion Biotech's valuation are provided below:
Gross Profit
7.7 M
Profit Margin
(0.71)
Market Capitalization
40 M
Enterprise Value Revenue
4.6823
Revenue
7.7 M
We have found one hundred twenty available fundamental signals for Evaxion Biotech AS, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Evaxion Biotech AS prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 5 M in 2026. Enterprise Value is likely to drop to about 10.5 M in 2026

Evaxion Biotech Total Revenue

4.04 Million

Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 277.5 K, Depreciation And Amortization of 376.7 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 1.48, Dividend Yield of 0.0 or Days Sales Outstanding of 162. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
  
Build AI portfolio with Evaxion Stock
Check out the analysis of Evaxion Biotech Correlation against competitors.

Evaxion Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.8 M14.4 M10.2 M
Slightly volatile
Short and Long Term Debt Total6 M11.6 M3.7 M
Slightly volatile
Other Current Liabilities1.4 M1.1 M818.4 K
Slightly volatile
Total Current Liabilities4.9 M5 M2.8 M
Slightly volatile
Property Plant And Equipment Net2.5 M4 M1.6 M
Slightly volatile
Accounts Payable2.1 M3.4 M1.2 M
Slightly volatile
Cash10.9 M5.8 M5.8 M
Slightly volatile
Non Current Assets Total2.8 M4.3 M1.7 M
Slightly volatile
Cash And Short Term Investments10.9 M5.8 M5.8 M
Slightly volatile
Net Receivables1.6 M2.1 M1.8 M
Slightly volatile
Common Stock Shares Outstanding917.3 K965.6 K8 M
Slightly volatile
Liabilities And Stockholders Equity16.8 M14.4 M10.2 M
Slightly volatile
Non Current Liabilities Total11.8 M11.2 M3.6 M
Slightly volatile
Capital Lease Obligations1.3 M2.2 M816.3 K
Slightly volatile
Other Current Assets2.4 M2.1 M1.4 M
Slightly volatile
Total Liabilities9.6 M16.3 M5.8 M
Slightly volatile
Net Invested Capital12 M7.5 M7.3 M
Slightly volatile
Total Current Assets14 M10.1 M8.5 M
Slightly volatile
Short Term Debt404.4 K425.7 K699.7 K
Very volatile
Common Stock12.7 M12.1 M4.3 M
Slightly volatile
Short and Long Term Debt135.9 K143.1 K4.6 M
Slightly volatile
Capital Stock12.7 M12.1 M4.3 M
Slightly volatile
Property Plant Equipment6.2 M6 M2 M
Slightly volatile
Property Plant And Equipment Gross4.2 M5.8 M2.1 M
Slightly volatile
Intangible Assets77.2 K83.7 K96.1 K
Slightly volatile
Other Liabilities122.4 K137.7 K150.3 K
Slightly volatile
Long Term Debt7 M9.2 M3.1 M
Slightly volatile
Current Deferred Revenue1.61.81.9647
Slightly volatile
Short Term Investments132148162
Slightly volatile
Non Current Liabilities Other8 K9 K9.8 K
Slightly volatile

Evaxion Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income277.5 K292.1 K487.1 K
Slightly volatile
Depreciation And Amortization376.7 K698 K239 K
Slightly volatile
Interest Expense1 M1.1 M830.9 K
Slightly volatile
Selling General Administrative6.6 M8.4 M4.2 M
Slightly volatile
Other Operating Expenses19.6 M20.8 M12.4 M
Slightly volatile
Research Development13.1 M12 M8.1 M
Slightly volatile
Cost Of Revenue122129104 K
Very volatile
Total Operating Expenses19.6 M20.8 M12.4 M
Slightly volatile
Reconciled Depreciation376.7 K698 K239 K
Slightly volatile
Selling And Marketing Expenses220 K247.5 K270.1 K
Slightly volatile

Evaxion Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation305.2 K321.3 K1.7 M
Slightly volatile
Begin Period Cash Flow11.7 M6.4 M5.7 M
Slightly volatile
Depreciation376.7 K698 K239 K
Slightly volatile
Capital Expenditures4.014.22132.7 K
Pretty Stable
Change To Operating Activities18 K18.9 K327.8 K
Slightly volatile
Issuance Of Capital Stock15.6 M19 M8.4 M
Slightly volatile
Total Cash From Financing Activities17.1 M15.1 M12.5 M
Slightly volatile
End Period Cash Flow9.1 M5.4 M9 M
Pretty Stable
Change To Netincome870.4 K916.2 K2 M
Slightly volatile
Dividends Paid132 K148.5 K162.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.481.56265
Slightly volatile
Days Sales Outstanding162183199
Slightly volatile
Stock Based Compensation To Revenue0.120.10685.4241
Slightly volatile
Capex To Depreciation0.150.160.6171
Pretty Stable
EV To Sales3.133.3324
Slightly volatile
Payables Turnover0.140.12540.3423
Slightly volatile
Sales General And Administrative To Revenue2.392.52114
Slightly volatile
Research And Ddevelopement To Revenue3.423.6135
Slightly volatile
Capex To Revenue0.951.071.1704
Slightly volatile
Cash Per Share5.145.4217.0083
Very volatile
Days Payables Outstanding1.4 K2.6 K1.6 K
Slightly volatile
Income Quality0.671.10.6172
Slightly volatile
Intangibles To Total Assets0.00250.00270.0063
Slightly volatile
Current Ratio2.192.315.9997
Slightly volatile
Receivables Turnover1.441.621.768
Slightly volatile
Capex Per Share0.110.12730.2958
Slightly volatile
Revenue Per Share2.952.810.6101
Slightly volatile
Interest Debt Per Share9.159.2814.9791
Slightly volatile
Debt To Assets0.760.730.3037
Slightly volatile
Days Of Payables Outstanding1.4 K2.6 K1.6 K
Slightly volatile
Ebt Per Ebit1.080.891.0449
Slightly volatile
Effective Tax Rate0.06640.07980.0887
Slightly volatile
Long Term Debt To Capitalization0.811.130.3717
Slightly volatile
Total Debt To Capitalization1.131.080.4374
Slightly volatile
Quick Ratio2.192.316.0082
Slightly volatile
Net Income Per E B T0.750.840.8958
Very volatile
Cash Ratio1.261.332.08
Pretty Stable
Days Of Sales Outstanding162183199
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9927
Slightly volatile
Fixed Asset Turnover0.90.860.1733
Slightly volatile
Debt Ratio0.760.730.3037
Slightly volatile
Price Sales Ratio1.481.56265
Slightly volatile
Asset Turnover0.250.240.0492
Slightly volatile

Evaxion Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5 M5.2 M160.9 M
Slightly volatile
Enterprise Value10.5 M11 M160.1 M
Slightly volatile

Evaxion Fundamental Market Drivers

Forward Price Earnings3.5714
Cash And Short Term Investments5.1 M

Evaxion Upcoming Events

25th of April 2024
Upcoming Quarterly Report
View
29th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Evaxion Biotech Financial Statements

Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.80  1.60 
Total Revenue3.8 M4 M
Cost Of Revenue 128.80  122.36 
Stock Based Compensation To Revenue 0.11  0.12 
Sales General And Administrative To Revenue 2.52  2.39 
Research And Ddevelopement To Revenue 3.60  3.42 
Capex To Revenue 1.07  0.95 
Revenue Per Share 2.81  2.95 
Ebit Per Revenue(3.96)(4.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY